natgillin/translations-raw huggingface dataset:
Detailed instructions on how to take aniseed medicines and who can use them can be found in the package leaflet that comes with the medicine.
Podrobna navodila o jemanju zdravil, ki vsebujejo plod vrtnega janeža, in o tem, kdo sme ta zdravila jemati, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
What evidence supports the use of aniseed medicines?
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo plod vrtnega janeža?
What are the risks associated with aniseed medicines?
Kakšna tveganja so povezana z zdravili, ki vsebujejo plod vrtnega janeža?
For more information about treatment with aniseed medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravili, ki vsebujejo plod vrtnega janeža, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using aniseed medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
Other information about aniseed medicines
Druge informacije o zdravilih, ki vsebujejo plod vrtnega janeža
What is aniseed?
Kaj je plod vrtnega janeža?
Aniseed
delavcem.
Date of first authorisation: 11 November 2003 Date of latest renewal: 22 September 2008
Datum prve odobritve: 11. november 2003 Datum zadnjega podaljšanja: 22. september 2008
The storage details, should you need them, are as follows:
Pogoji shranjevanja, če bi jih potrebovali, so naslednji:
Time (hours)
Čas (ure) Time (hours)
No new safety concerns were identified.
Novih zadržkov glede varnosti niso ugotovili.
(IUDs) that release hormones.
(IUD), ki sproščajo hormone.
However, the data from this small study do not support a conclusion on the optimal dosing regimen.
Vendar podatki iz te majhne študije ne podpirajo sklepa o optimalni shemi odmerjanja.
Statistically significant differences in efficacy were also observed in each of the 2 individual studies.
Statistično pomembne razlike v učinkovitosti so sicer opazili v vsaki od obeh študij.
**N: Number of patients included in the primary analysis of complete response.
**N: Število bolnikov, vključenih v primarno analizo popolnega odziva.
The median tmax was 3.0 hours.
Srednji tmax je bil 3,0 ure.
This is normal and the medicine is okay to use.
To je normalno in zdravilo se lahko uporabi.
It is very important that this medicine is given exactly as directed below.
Zelo pomembno je, da se to zdravilo daje natančno po navodilih spodaj.
The majority of adults were women (> 90 %), mainly undergoing gynaecological surgery.
Večina odraslih je bila žensk (> 90 %), pretežno po prestanih ginekoloških operativnih posegih.
The results were evaluated for each individual study and for the 2 studies combined.
Rezultate so ovrednotili za vsako posamezno študijo ter za kombinacijo obeh študij.
25-120 hours
25-120 ur
This medicine can affect other medicines.
To zdravilo lahko vpliva na druga zdravila.
Make sure no air is in the oral dispenser (if air is present, remove).
Prepričajte se, da v odmerniku ni zraka (če je zrak prisoten, ga odstranite).
These may not work properly when taken with this medicine.
Možno je, da ta sredstva med jemanjem tega zdravila ne delujejo ustrezno.
Summary of the safety profile The safety profile of aprepitant was evaluated in approximately 6,500 adults.
Povzetek varnostnega profila Varnostne značilnosti aprepitanta so ocenili pri približno 6.500 odraslih.
Other side effects that have been reported are listed below.
Ostali neželeni učinki, o katerih so poročali, so navedeni spodaj.
Unopened sachet: 2 years
Neodprta vrečka: 2 leti
The efficacy of the aprepitant regimen was apparently maintained during all cycles.
Učinkovitost aprepitanta se je očitno ohranjala v vseh ciklusih.
*Reported in patients taking a higher dose of aprepitant.
*Poročano pri bolnikih, ki jemljejo večji odmerek aprepitanta.
- If there is any foam, wait for the foam to disappear before going on to Step 9.
- Če je prisotna pena, počakajte, da pena izgine, preden nadaljujete z 9. korakom.
Aprepitant is not excreted unchanged in urine.
Aprepitant se ne izloča nespremenjen z urinom.
The terminal half-life ranged from approximately 9 to 13 hours.
Končni razpolovni čas je znašal v razponu od približno 9 do 13 ur.
- It is common to have medicine leftover in the cup.
- Običajno je, da nekaj zdravila ostane v čaši.
To prevent foaming, do not shake the mixing cup.
Da preprečite penjenje, ne stresajte čaše za mešanje.
Complete response (0-24 hours)
Popoln odziv (0-24 ur)
The efficacy of the aprepitant regimen was evaluated in a single cycle (Cycle 1).
Učinkovitost sheme z aprepitantom so ocenili v enem samem ciklusu (1. ciklus).
Do not remove all capsules at one time.
Ne odstranite vseh kapsul iz ovojnine naenkrat.
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adolescents (aged 12 through 17 years)
Mladostniki (stari od 12 do 17 let)
Both clearance and absolute bioavailability decrease with increasing dose.
Tako očistek kot absolutna biološka uporabnost se zmanjšujeta z večanjem odmerka.
†Difference and confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for Gender.
†Razlika in interval zaupanja (IZ) sta bila izračunana z uporabo metode po Miettinenu in Nurminenu in sta bila prilagojena glede na spol.
Patients had the opportunity to receive open-label aprepitant in subsequent cycles (Optional Cycles 2-6); however efficacy was not assessed in these optional cycles.
Bolniki so imeli možnost v naslednjih ciklusih (na izbiro od 2. do 6. ciklusa) odprto prejemati aprepitant, vendar učinkovitosti v teh neobveznih ciklusih niso ocenili.
Aprepitant is excreted in the milk of lactating rats.
Aprepitant se izloča v mleko podgan.
Do not remove the capsule from its blister until you are ready to take it.
Kapsule ne vzemite iz pretisnega omota, dokler je ne nameravate zaužiti.
The geometric mean apparent volume of distribution at steady state (Vdss) is approximately 66 L in humans.
Geometrični srednji navidezni volumen porazdelitve v stanju dinamičnega ravnovesja (Vdss) je pri ljudeh približno 66 l.
* - Delayed phase
* - zapoznela faza
Any unused medicinal product or waste material should be disposed of in accordance with local regulations.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
1-day regimen of fosaprepitant 150 mg in adults
1-dnevni režim zdravljenja s fosaprepitantom 150 mg pri odraslih
Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.
Poleg tega je posebna previdnost potrebna pri sočasni uporabi irinotekana, saj lahko kombinacija poveča toksični učinek.
The color of the medicine in the oral dispenser may be different shades of pink (light pink to dark pink).
Barva zdravila v odmerniku je lahko različen odtenek rožnate (svetlo do temno rožnat).
- if the child is using medicines that contain ‘pimozide' (for mental health problems).
- če otrok uporablja zdravila, ki vsebujejo pimozid (za težave z duševnim zdravjem).
The safety profile of aprepitant was evaluated in approximately 6,500 adults in more than 50 studies and 184 children and adolescents in 2 pivotal paediatric clinical trials.
Varnostne značilnosti aprepitanta so ocenili pri približno 6.500 odraslih v več kot 50 študijah ter 184 otrocih in mladostnikih v 2 kontroliranih pediatričnih kliničnih preskušanjih.
WHEN:
KDAJ:
WHEN and HOW to take EMEND
KDAJ in KAKO jemati zdravilo EMEND
Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12
Farmakoterapevtska skupina: Antiemetiki in zdravila proti slabosti, oznaka ATC: A04AD12
• For more details on preparation and administration of the suspension, see the package leaflet and the instructions for preparation of the oral suspension for healthcare professionals.
• Za podrobnosti o pripravi in uporabi suspenzije glejte Navodilo za uporabo in navodila za pripravo peroralne suspenzije za zdravstveno osebje.
Healthcare professionals: See the instructions for preparation of the oral suspension for healthcare professionals at the end of this package leaflet.
Zdravstveno osebje: Glejte navodila za pripravo peroralne suspenzije za zdravstveno osebje na koncu tega Navodila za uporabo.
The safety and exploratory efficacy of aprepitant were evaluated in a Phase I clinical study (n=50) using a 40 mg powder for oral suspension.
Varnost in učinkovitost aprepitanta so ocenili v klinični študiji I. faze (n = 50) z uporabo 40 mg praška za peroralno suspenzijo.
* - Overall phase
* - celotna faza
Mix the EMEND suspension gently by swirling 20 times; then gently invert the mixing cup 5 times.
EMEND suspenzijo nežno premešajte s tem, da jo 20-krat nežno zavrtite, nato čašo za mešanje nežno 5-krat obrnite.
Intravenous dexamethasone was permitted as part of the antiemetic regimen for paediatric patients in both age groups, at the discretion of the physician.
Uporaba intravenskega deksametazona je bila dovoljena kot del antiemetične sheme pri pediatričnih bolnikih v obeh starostnih skupinah, po zdravnikovi presoji.
Different pack sizes are available:
Na voljo so različna pakiranja:
Emend will generally be stored by healthcare professionals.
Zdravilo Emend bo praviloma shranjevalo zdravstveno osebje.
If you forget to give EMEND
Če ste pozabili dati zdravilo EMEND
Before reconstitution:
Pred pripravo:
Ondansetron was given intravenously immediately before induction of anaesthesia.
Ondansetron so prejeli intravensko neposredno pred uvodom v anestezijo.
Most adverse reactions reported in these clinical studies were described as mild to moderate in intensity.
Večino neželenih reakcij, o katerih so poročali v teh kliničnih študijah, so opisali kot blage do zmerne.
p < 0.01 when compared to control regimen p < 0.05 when compared to control regimen No vomiting = No vomiting or retching or dry heaves n/m = Number of patients with desired response/number of patients included in time point.
p < 0,01 v primerjavi s kontrolno shemo p < 0,05 v primerjavi s kontrolno shemo Brez bruhanja = brez bruhanja ali bljuvanja ali siljenja na bruhanje n/m = število bolnikov z želenim odzivom/število vseh vključenih bolnikov na določeni časovni točki.
If the child feels dizzy or sleepy, they should not ride a bicycle or use any tools or machines.
Če je otrok omotičen ali zaspan, se ne sme voziti s kolesom ali uporabljati orodij ali strojev.
Swallow the capsule whole with some liquid.
Kapsulo pogoltnite celo, z nekaj tekočine.
Other medicines and EMEND
Druga zdravila in zdravilo EMEND
Efficacy data in combination with other corticosteroids and 5-HT3 antagonists are limited.
Podatkov o učinkovitosti v kombinaciji z drugimi kortikosteroidi in antagonisti 5-HT3 je malo.
For details on preparation and administration of the suspension, see section 6.6.
Za podrobnosti o pripravi in uporabi suspenzije glejte poglavje 6.6.
• Once mixed, measure the recommended volume (dose) of suspension with the oral dispenser.
• Ko je zdravilo zmešano, odmerite priporočeno količino (odmerek) suspenzije z odmernikom.
Complete response
Popoln odziv
The potential effects on reproduction of alterations in neurokinin regulation are unknown.
Morebitni učinki sprememb regulacije nevrokininov na sposobnost razmnoževanja niso znani.
The doctor may therefore have to monitor the condition of your or the child's liver.
Zdravnik bo zato morda moral spremljati stanje vaših ali otrokovih jeter.
Other pharmaceutical forms/strengths may be more appropriate for administration to this population.
Za uporabo pri tej populaciji so bolj primerne druge farmacevtske oblike oziroma jakosti.
Stop giving this medicine and see a doctor straight away if you notice any of the serious side effects above.
Nehajte dajati to zdravilo in takoj obiščite zdravnika, če opazite katerega od zgoraj naštetih resnih neželenih učinkov.
This effect may become apparent only after the end of a 3-day treatment with EMEND.
Ta učinek se lahko pokaže šele po koncu 3-dnevnega zdravljenja z zdravilom EMEND.
For additional information on the co-administration with corticosteroids, see section 4.5.
Za dodatne informacije o sočasni uporabi s kortikosteroidi glejte poglavje 4.5.
This effect may become apparent approximately 7 days following the single dose administration of EMEND 165 mg.
Ta učinek lahko nastopi približno 7 dni po zaužitju enkratnega odmerka zdravila EMEND 165 mg.
The benefit of aprepitant combination therapy in the full study population was mainly driven by the results observed in patients with poor control with the standard regimen such as in women, even though the results were numerically better regardless of age, tumour type or gender.
Korist kombiniranega zdravljenja z aprepitantom v popolni populacijski študiji je temeljila zlasti na rezultatih, ki so jih opazili pri slabo nadzorovanih bolnikih na standardni obliki zdravljenja, npr. pri ženskah, pa čeprav so bili rezultati številčno boljši ne glede na starost, tip tumorja ali spol.
Make sure the oral dispenser contains the prescribed dose.
Prepričajte se, da odmernik vsebuje predpisani odmerek.
For each dose of EMEND, you will get a pre-filled oral dispenser that contains the child's prescribed dose.
Za vsak odmerek zdravila EMEND boste dobili napolnjen odmernik, ki vsebuje predpisani odmerek za otroka.
A population pharmacokinetic analysis of aprepitant in paediatric patients (aged 6 months through 17 years) suggests that gender and race have no clinically meaningful effect on the pharmacokinetics of aprepitant.
Populacijska farmakokinetična analiza aprepitanta pri pediatričnih bolnikih (starih od 6 mesecev do 17 let) kaže, da spol in rasa nimata klinično pomembnega vpliva na farmakokinetiko aprepitanta.
No dose adjustment is recommended.
Prilagajanja odmerka ne priporočamo.
This tells you how to prepare a dose of EMEND as an oral suspension.
Tam je navedeno, kako pripraviti odmerek zdravila EMEND v obliki peroralne suspenzije.
Aprepitant has been studied at higher doses.
Aprepitant so raziskovali tudi pri višjih odmerkih.
For aprepitant no clinical data on exposed pregnancies are available.
Za aprepitant ni na voljo kliničnih podatkov za nosečnice, ki so bile izpostavljene zdravilu.
Patients receiving the aprepitant regimen were receiving chemotherapy for a variety of tumour types including 52 % with breast cancer, 21 % with gastrointestinal cancers including colorectal cancer, 13 % with lung cancer and 6 % with gynaecological cancers.
Bolniki, ki so prejemali aprepitant, so dobivali kemoterapijo zaradi različnih tipov tumorja, med njimi 52 % bolnikov zaradi raka na dojkah, 21 % zaradi gastrointestinalnega raka, vključno s kolorektalnim rakom, 13 % zaradi pljučnega raka in 6 % zaradi raka rodil.
OUTER PACKAGING - STANDARD PACK (CARTON)
ZUNANJA OVOJNINA - STANDARDNO PAKIRANJE (ŠKATLA)
Aprepitant is highly protein bound, with a mean of 97 %.
Aprepitant se močno veže na beljakovine, povprečno 97-odstotno.
The antiemetic activity of aprepitant was evaluated during the 0 to 48 hour period following the end of surgery.
Antiemetični učinek aprepitanta so vrednotili od 0 do 48 ur po koncu operacije.
For short term treatment according to recommended dose regimen these findings are considered unlikely to be clinically relevant.
Za kratkotrajno uporabo v skladu s priporočeno shemo odmerjanja ti izsledki niso klinično pomembni.
Talk to the doctor, pharmacist or nurse if the child is taking any of the following medicines: - medicines that affect the immune system - such as cyclosporine, tacrolimus, sirolimus,
Obvestite zdravnika, farmacevta ali medicinsko sestro, če otrok jemlje katero od naslednjih zdravil: - zdravila, ki vplivajo na imunski sistem - na primer ciklosporin, takrolimus, sirolimus,
§ - Overall phase Complete response = No vomiting or retching or dry heaves and no use of rescue medication.
§ - celotna faza Popoln odziv = brez bruhanja ali bljuvanja ali siljenja na bruhanje in brez uporabe rešilnega zdravila.
EMEND oral suspension
EMEND peroralna suspenzija
Fosaprepitant regimen (N =1,106) **
Fosaprepitant (N = 1,106) **
The percentage of subjects reporting no vomiting over the first 24 hours following surgery was similar for subjects receiving aprepitant versus ondansetron.
Odstotek preiskovancev, ki v prvih 24 urah po operaciji niso poročali o bruhanju, je bil med preiskovanci, ki so prejemali aprepitant, podoben kot med tistimi, ki so prejemali ondansetron.
Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days.
Blaga indukcija glukuronidacije je vidna tudi pri 80 mg peroralnem aprepitantu, ki se ga daje 7 dni.
Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2 % of the dose was recovered in the dialysate.
Hemodializa, opravljena 4 ali 48 ur po odmerjanju, ni pomembno vplivala na farmakokinetiko aprepitanta; v dializatu se je izločilo manj kot 0,2 % odmerka.
In the event of overdose, EMEND should be discontinued and general supportive treatment and monitoring should be provided.
V primeru prevelikega odmerjanja je treba prekiniti zdravljenje z zdravilom EMEND ter bolniku nuditi splošno podporno zdravljenje in nadzor.
The plasma AUC of midazolam was increased by 1.5-fold.
Plazemske vrednosti AUC midazolama so se povečale za 1,5-krat.
What EMEND is and what it is used for
Kaj je zdravilo EMEND in za kaj ga uporabljamo
Complete response to the aprepitant regimen and standard therapy, respectively, was reached in 209/324 (65 %) and 161/320 (50 %) in women and 83/101 (82 %) and 68/87 (78 %) of men.
Popoln odziv na aprepitant je bil dosežen pri 209/324 (65 %) ženskah in 83/101 (82 %) moških, na standardno obliko zdravljenja pa pri 161/320 (50 %) ženskah in 68/87 (78 %) moških.
Some less common ADRs in the adult population were not observed in the paediatric studies.
O nekaterih manj pogostih neželenih učinkih pri odrasli populaciji v pediatričnih študijah niso poročali.
Method of administration The hard capsule should be swallowed whole.
Trdo kapsulo je treba pogoltniti celo.
Hold the EMEND powder for oral suspension sachet upright and shake the contents to the bottom before opening the sachet.
Vrečko zdravila EMEND prašek za peroralno suspenzijo držite pokonci in vsebino pretresite na dno, preden jo odprete.
To remove, push capsules through from this side.
Za odstranitev kapsule iz ovojnine pritisnite tu.
Day 2 and Day 3: - If the child will not have chemotherapy - give this medicine in the morning.
2. in 3. dan: - Če otrok ne bo dobil kemoterapije, mu zdravilo dajte zjutraj.
If a corticosteroid, such as dexamethasone, is co-administered with EMEND, the dose of the corticosteroid should be administered at 50 % of the usual dose (see sections 4.5 and 5.1).
Če je sočasno z zdravilom EMEND uporabljen kortikosteroid, kot je deksametazon, je treba odmerek kortikosteroida zmanjšati na 50 % običajnega odmerka (glejte poglavji 4.5 in 5.1).
Efficacy was based on the evaluation of the following primary and key secondary endpoints: No vomiting in the overall period (0 to 120 hours post-chemotherapy), evaluation of safety and tolerability of the aprepitant regimen for chemotherapy induced nausea and vomiting (CINV), and complete response (defined as no vomiting and no use of rescue therapy) in the overall period (0 to 120 hours post-chemotherapy).
Učinkovitost zdravljenja je temeljila na naslednjih primarnih in ključnih sekundarnih opazovanih dogodkih: odsotnost bruhanja v celotnem obdobju (0 do 120 ur po kemoterapiji), ocena varnosti in prenašanja aprepitanta pri zdravljenju navzee in bruhanja zaradi kemoterapije (CINV) ter popoln odziv (opredeljen kot odsotnost bruhanja in brez rešilnega zdravljenja) v celotnem obdobju (0 do 120 ur po kemoterapiji).
Fosaprepitant 150 mg was shown to be non-inferior to that of the 3-day regimen of aprepitant.
Izkazalo se je, da fosaprepitant 150 mg ni slabši v primerjavi s 3-dnevnim režimom zdravljenja z aprepitantom.
Please read enclosed leaflet before use.
Pred uporabo preberite priloženo navodilo!
Fill the mixing cup with room temperature drinking water.
V čašo za mešanje dodajte pitno vodo sobne temperature.
If no chemotherapy is given on Days 2 and 3, EMEND should be administered in the morning.
Če 2. in 3. dan ni uporabljena kemoterapija, je treba zdravilo EMEND uporabiti zjutraj.
OTHER PRESPECIFIED ENDPOINTS Complete response
DRUGI VNAPREJ OPREDELJENI OPAZOVANI DOGODKI Popoln odziv
Take one EMEND 80 mg capsule each morning.
Vzemite eno EMEND 80 mg kapsulo vsako jutro.
Ondansetron 4 mg intravenously (N=526)
ondansetron 4 mg intravensko (N=526)
Aprepitant 40 mg orally (N=541)
aprepitant 40 mg peroralno (N=541)
Days 2 and 3: - one 80 mg capsule each day - If no chemotherapy is given, take EMEND in the morning.
2. in 3. dan: - ena 80 mg kapsula vsak dan - Tiste dni, ko ne dobite kemoterapije, zdravilo EMEND vzemite zjutraj.
Aprepitant regimen (N =1,134) **
Aprepitant (N = 1,134) **
The recommended dose of EMEND powder for oral suspension is based on weight, as specified in the table below.
Priporočeni odmerek zdravila EMEND prašek za peroralno suspenzijo temelji na telesni masi, kot je prikazano v spodnji preglednici.
The estimated time to first vomiting after initiation of chemotherapy treatment was longer with the aprepitant regimen (estimated median time to first vomiting was 94.5 hours) compared with the control regimen group (estimated median time to first vomiting was 26.0 hours) as depicted in the Kaplan-Meier curves in Figure 2.
Ocenjeni čas do prvega bruhanja po uvedbi kemoterapije je bil pri shemi z aprepitantom daljši (ocenjeni mediani čas do prvega bruhanja je bil 94,5 ure) kot pri kontrolni shemi (ocenjeni mediani čas do prvega bruhanja je bil 26,0 ur), kot prikazujeta Kaplan-Meierjevi krivulji na sliki 2.
Different pack sizes including different strengths are available.
Na voljo so različna pakiranja, ki vsebujejo različne jakosti zdravila.
Aprepitant was given orally with 50 mL of water 1 to 3 hours before anaesthesia.
Aprepitant so prejeli peroralno s 50 ml vode 1 do 3 ure pred anestezijo.
The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table.
Kategorije pogostnosti neželenih učinkov, navedene v preglednici, temeljijo na študijah pri odraslih; v pediatričnih študijah so bile pogostnosti podobne ali manjše, razen če je v preglednici navedeno drugače.
It is not known whether EMEND is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine.
Ni znano, ali se zdravilo EMEND izloča v materino mleko, zato se dojenje v času jemanja tega zdravila ne priporoča.
• Discard any remaining suspension and waste material.
• Vso preostalo suspenzijo in odpadni material zavrzite.
In the same clinical study, 744 adult patients continued into the Multiple-Cycle extension for up to 3 additional cycles of chemotherapy.
V isti klinični študiji je 744 odraslih bolnikov nadaljevalo v podaljšku z več ciklusi, in sicer do 3 dodatne cikluse kemoterapije.
Also, some other medicines can affect the way this medicine works.
Prav tako lahko nekatera druga zdravila vplivajo na delovanje zdravila EMEND.
Occupancy of brain NK1 receptors by aprepitant correlate well with aprepitant plasma concentrations.
Zasedenost možganskih receptorjev NK1 z aprepitantom dobro sovpada s plazemskimi koncentracijami aprepitanta.